| Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders J Aron-Wisnewsky, C Vigliotti, J Witjes, P Le, AG Holleboom, J Verheij, ... Nature Reviews Gastroenterology & Hepatology 17 (5), 279-297, 2020 | 840 | 2020 |
| Genetic variant of the scavenger receptor BI in humans M Vergeer, SJA Korporaal, R Franssen, I Meurs, R Out, GK Hovingh, ... New England Journal of Medicine 364 (2), 136-145, 2011 | 384 | 2011 |
| The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? M Vergeer, AG Holleboom, JJP Kastelein, JA Kuivenhoven Journal of lipid research 51 (8), 2058-2073, 2010 | 308 | 2010 |
| Compromised LCAT function is associated with increased atherosclerosis GK Hovingh, BA Hutten, AG Holleboom, W Petersen, P Rol, A Stalenhoef, ... Circulation 112 (6), 879-884, 2005 | 224 | 2005 |
| TNFα induces ABCA1 through NF-κB in macrophages and in phagocytes ingesting apoptotic cells MC Gerbod-Giannone, Y Li, A Holleboom, S Han, LC Hsu, I Tabas, ... Proceedings of the National Academy of Sciences 103 (9), 3112-3117, 2006 | 138 | 2006 |
| Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis JJ Witjes, LP Smits, CT Pekmez, A Prodan, AS Meijnikman, MA Troelstra, ... Hepatology communications 4 (11), 1578-1590, 2020 | 130 | 2020 |
| Microbiome-derived ethanol in nonalcoholic fatty liver disease AS Meijnikman, M Davids, H Herrema, O Aydin, V Tremaroli, ... Nature medicine 28 (10), 2100-2106, 2022 | 128 | 2022 |
| Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism R Karuna, R Park, A Othman, AG Holleboom, MM Motazacker, I Sutter, ... Atherosclerosis 219 (2), 855-863, 2011 | 124 | 2011 |
| NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? D Stols-Gonçalves, GK Hovingh, M Nieuwdorp, AG Holleboom Trends in Endocrinology & Metabolism 30 (12), 891-902, 2019 | 123 | 2019 |
| The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease T Hardy, K Wonders, R Younes, GP Aithal, R Aller, M Allison, P Bedossa, ... Contemporary clinical trials 98, 106175, 2020 | 122 | 2020 |
| CCDC115 deficiency causes a disorder of Golgi homeostasis with abnormal protein glycosylation JC Jansen, S Cirak, M Van Scherpenzeel, S Timal, J Reunert, S Rust, ... The American Journal of Human Genetics 98 (2), 310-321, 2016 | 116 | 2016 |
| Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man AG Holleboom, H Karlsson, RS Lin, TM Beres, JA Sierts, DS Herman, ... Cell metabolism 14 (6), 811-818, 2011 | 114 | 2011 |
| Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta … FE Mózes, JA Lee, Y Vali, O Alzoubi, K Staufer, M Trauner, R Paternostro, ... The Lancet Gastroenterology & Hepatology 8 (8), 704-713, 2023 | 113 | 2023 |
| Anti-hyperlipidemic effect of an edible brown algae, Ecklonia stolonifera, and its constituents on poloxamer 407-induced hyperlipidemic and cholesterol-fed rats NY Yoon, HR Kim, HY Chung, JS Choi Archives of pharmacal research 31, 1564-1571, 2008 | 112 | 2008 |
| The role of lipophagy in the development and treatment of non-alcoholic fatty liver disease A Grefhorst, IP van de Peppel, LE Larsen, JW Jonker, AG Holleboom Frontiers in endocrinology 11, 601627, 2021 | 98 | 2021 |
| Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study Y Vali, J Lee, J Boursier, S Petta, K Wonders, D Tiniakos, P Bedossa, ... The Lancet Gastroenterology & Hepatology 8 (8), 714-725, 2023 | 95 | 2023 |
| TMEM199 deficiency is a disorder of Golgi homeostasis characterized by elevated aminotransferases, alkaline phosphatase, and cholesterol and abnormal glycosylation JC Jansen, S Timal, M Van Scherpenzeel, H Michelakakis, D Vicogne, ... The American Journal of Human Genetics 98 (2), 322-330, 2016 | 95 | 2016 |
| ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden AE Bochem, DF van Wijk, AG Holleboom, R Duivenvoorden, ... European heart journal 34 (4), 286-291, 2013 | 90 | 2013 |
| Plasma levels of lecithin: cholesterol acyltransferase and risk offuture coronary artery disease in apparently healthy men and women: aprospective case-control analysis nested … AG Holleboom, JA Kuivenhoven, M Vergeer, GK Hovingh, JN van Miert, ... Journal of lipid research 51 (2), 416-421, 2010 | 88 | 2010 |
| The value of HDL genetics AG Holleboom, M Vergeer, GK Hovingh, JJP Kastelein, JA Kuivenhoven Current opinion in lipidology 19 (4), 385-394, 2008 | 88 | 2008 |
